ArTS Archivio della ricerca di Trieste

BERGAMO, ALBERTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.498
AS - Asia 4.901
EU - Europa 4.611
SA - Sud America 712
Continente sconosciuto - Info sul continente non disponibili 313
AF - Africa 116
OC - Oceania 12
Totale 21.163
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.344
SG - Singapore 1.879
CN - Cina 1.152
PL - Polonia 777
IT - Italia 716
UA - Ucraina 628
SE - Svezia 611
BR - Brasile 540
HK - Hong Kong 508
VN - Vietnam 499
DE - Germania 381
KR - Corea 269
GB - Regno Unito 263
FI - Finlandia 255
FR - Francia 254
RU - Federazione Russa 240
TR - Turchia 156
BG - Bulgaria 145
IE - Irlanda 128
BD - Bangladesh 126
IN - India 80
AR - Argentina 73
CA - Canada 68
NL - Olanda 57
MX - Messico 42
CH - Svizzera 32
ES - Italia 31
IQ - Iraq 30
JP - Giappone 27
EC - Ecuador 24
ZA - Sudafrica 24
ID - Indonesia 23
MA - Marocco 23
CO - Colombia 21
PY - Paraguay 20
SA - Arabia Saudita 19
AT - Austria 17
BE - Belgio 15
UZ - Uzbekistan 15
KE - Kenya 14
PH - Filippine 14
EU - Europa 13
VE - Venezuela 13
PK - Pakistan 12
SN - Senegal 11
TW - Taiwan 11
RO - Romania 10
AU - Australia 9
CL - Cile 9
JO - Giordania 9
TH - Thailandia 9
DZ - Algeria 8
EG - Egitto 8
KZ - Kazakistan 8
MY - Malesia 8
JM - Giamaica 7
GR - Grecia 6
HN - Honduras 6
HU - Ungheria 6
IL - Israele 6
RS - Serbia 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
NG - Nigeria 5
NP - Nepal 5
PT - Portogallo 5
QA - Qatar 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
AL - Albania 4
CZ - Repubblica Ceca 4
IR - Iran 4
KW - Kuwait 4
PE - Perù 4
BW - Botswana 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
DK - Danimarca 3
ET - Etiopia 3
GT - Guatemala 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
SK - Slovacchia (Repubblica Slovacca) 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BO - Bolivia 2
BY - Bielorussia 2
GA - Gabon 2
GE - Georgia 2
HR - Croazia 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LT - Lituania 2
MN - Mongolia 2
PA - Panama 2
PR - Porto Rico 2
SV - El Salvador 2
AG - Antigua e Barbuda 1
Totale 20.842
Salva come PNG Salva come JPEG
Città #
Singapore 1.165
Ashburn 893
Ann Arbor 857
Fairfield 793
Woodbridge 753
Houston 666
Warsaw 641
San Jose 598
Jacksonville 569
Chandler 511
Hong Kong 491
Wilmington 462
Seattle 337
Hefei 309
Beijing 275
Cambridge 268
Seoul 265
Princeton 247
Santa Clara 236
Council Bluffs 224
Boardman 197
Chicago 176
Columbus 171
Ho Chi Minh City 170
Los Angeles 143
Sofia 142
Trieste 135
Dublin 125
Izmir 123
Zgierz 122
Hanoi 118
Milan 116
Lauterbourg 110
Dallas 98
Dearborn 94
Buffalo 86
Moscow 82
The Dalles 75
San Diego 62
Helsinki 47
Frankfurt am Main 43
New York 43
Phoenix 43
São Paulo 43
Munich 41
London 37
Düsseldorf 29
Verona 27
Bern 26
Redwood City 25
Falls Church 23
Miano 22
Orem 22
Turku 22
Atlanta 21
Des Moines 21
Guangzhou 21
Nanjing 21
Tokyo 20
Rome 19
Da Nang 18
San Francisco 18
Norwalk 17
Rio de Janeiro 17
Denver 16
Montreal 16
Shanghai 16
Chennai 15
Mexico City 15
Poplar 15
Toronto 15
Brussels 14
Kunming 14
North Bergen 14
Tianjin 14
Biên Hòa 12
Casablanca 12
Haiphong 12
Hangzhou 12
Nairobi 12
Tashkent 12
Belo Horizonte 11
Brooklyn 11
Dakar 11
Johannesburg 11
Redmond 11
Vienna 11
Zhengzhou 11
Amsterdam 10
Andover 10
Brasília 10
Costa Mesa 10
Curitiba 10
Dhaka 10
Dong Ket 10
Jinan 10
Wuhan 10
Auburn Hills 9
Boston 9
Charlotte 9
Totale 14.021
Salva come PNG Salva come JPEG
Nome #
Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin 415
Pharmacological activities of ruthenium complexes related to their NO scavenging properties 374
Chemical and Molecular Approach to Tumor Metastases 353
Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A 297
Complessi dicarbossilati del rutenio(II) e loro impiego come antitumorali 262
Long non-coding RNA gas5 and intestinal mmp2 and mmp9 expression: A translational study in pediatric patients with IBD 259
Sulfoxide ruthenium complexes: non toxic tools for the selective treatment of solid tumour metastases. 255
Antimetastatic Action and Lymphocyte Activation by the Modified Lysozyme Lyso-M-PEG in Mice with Mca Mammary Carcinoma 248
Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors 244
Antimetastatic action and lymphocyte activation by the modified lysozyme mPEG-Lyso in mice with MCa mammary carcinoma 234
Dual action of NAMI-A in inhibition of solid tumor metastasis: Selective targeting of metastatic cells and binding to collagen 230
Ruthenium-Porphyrin Conjugates with Cytotoxic and Phototoxic Antitumor Activity 227
RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A 227
Phototoxic Activity and DNA Interactions of Water-Soluble Porphyrins and Their Rhenium(I) Conjugates 227
Reduction of lung metastases by Na[trans-RuCl4(DMSO)Im] is not coupled with the induction of chemical xenogenization 220
Complessi di Rutenio con elevata attività antitumorale 216
New half sandwich-type Ru(II) coordination compounds characterized by the fac-Ru(dmso-S)3 fragment: influence of the face-capping group on the chemical behavior and in vitro anticancer activity. 216
Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: the crystal structure of [ImH][trans-RhCl4(Im)2] (Im= imidazole) 215
Age Dependent Modification of the Metabolic Profile of the Tibialis Anterior Muscle Fibers in C57BL/6J Mice 215
Efficacy of 5-FU combined to Na[trans-RuCl4(DMSO)(Im)], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma 212
Is the aromatic fragment of piano-stool ruthenium compounds an essential feature for anticancer activity? The development of new Ru(II)-[9]aneS3 analogues. 211
Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[{trans-RuCl4(Me2SO)}2(μ-L)] (L=ditopic, non-chelating aromatic N-ligand). A preliminary investigation 210
The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions 206
Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A 205
Tuning the hydrophobicity of ruthenium(ii)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy 204
Ruthenium complexes can target determinants of tumour malignancy 203
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes 203
Effects of L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine on the antitumor action of cyclophosphamide, 5-FU, cisplatin and dacarbazine on advanced carcinomas of the mouse 203
Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A 202
Approaching tumour therapy beyond platinum drugs. Status of the art and perspectives of ruthenium drug candidates. 202
Half-sandwich RuIIsingle bond[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: Preparation, structural characterization and in vitro cytotoxic activity 201
Long-term resveratrol treatment improves the capillarization in the skeletal muscles of ageing C57BL/6J mice 200
Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir 199
Metal-based antitumour drugs in the post-genomic era: what comes next? 198
New half sandwich Ru(II) coordination compounds for anticancer activity 197
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs 196
Towards Matched Pairs of Porphyrin-ReI/99mTcIConjugates that Combine Photodynamic Activity with Fluorescence and Radio Imaging 196
Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. 194
Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data 194
Ruthenium antimetastatic agents 192
Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an antimetastatic ruthenium complex 191
Stimulation of GALT and Activation of Mesenteric Lymphonode Lymphocytes by a Modifìed Iysozyme in CBA Mice with Mca mammary carcinoma 190
Synthesis and characterization of a diruthenium(II,III)-ketoprofen compound and study of the in vitro effects on CRC cells in comparison to the naproxen and ibuprofen derivatives 190
Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity 190
Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells. 187
Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition 187
In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model 185
Ruthenium drugs for cancer chemotherapy: an ongoing challenge to treat solid tumours 184
Modulation of Activity of Known Cytotoxic Ruthenium(III) Compound (KP418) with Hampered Transmembrane Transport in Electrochemotherapy In Vitro and In Vivo 182
Down-regulation of tumor gelatinase/inhibitor balance and preservation of tumor endothelium by an anti-metastatic ruthenium complex. 182
Platinum(II) complexes with antitumoral/antiviral aromatic heterocycles: effect of glutathione upon in vitro cell growth inhibition 180
Cytofluorimetric analysis of gut-intraepitelial and mesenteric lymph node lymphocytes of tumour bearing mice fed with egg-white lysozyme 179
Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine 179
Ruthenium complexes with high antitumoral and antimetastatic activities 178
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound 176
Ruthenium-sulfoxide complexes with a specific antimetastatic activity 176
Ruthenium dimeric compounds suitable as antimetastatic and antineoplastic agents 175
In vitro cell cycle arrest, in vivo action on solid metastasizing tumors and host toxicity of the antimetastatic drug NAMI-A and of cisplatin. 174
Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion 174
Synthetic thymic fraction 5: Effects of high dose administration on circulating lymphocytes in patients 174
Photolabile RuIIHalf-Sandwich Complexes Suitable for Developing “Caged” Compounds: Chemical Investigation and Unexpected Dinuclear Species with Bridging Diamine Ligands 172
Preclinical combination therapy of the investigational drug NAMI-A with doxorubicin for mammary cancer 171
Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl(4)(Im)(DMSO)], (I) and of the orange form of [(DMSO)(2)H][trans-IrCl(4)(DMSO)(2)], (II), complexes. 169
Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds 166
Ruthenium Anticancer Drugs 165
Novel water-soluble 99mTc(I)/Re(I)-porphyrin conjugates as potential multimodal agents for molecular imaging 165
Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferring. 162
Synthesis, characterization and tumor cell growth inhibition of new transplatinum complexes with phosphane derivatives 161
Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation 161
CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2 161
Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells 159
Synthesis and Chemical-Pharmacological Characterization of the Antimetastatic NAMI-A-Type Ru(III) Complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-Dimethyl [1,2,4]triazolo [1,5-a]pyrimidine) 158
DNA-adduct formation-guided design: thoughts about the future of metal based anticancer drugs 158
Cytofluorimetric analysis of gut-intraepithelial and mesenteric lymph nodelymphocytes of tumour bearing mice fed with egg-white lysozyme. 156
Antimetastatic properties and DNA interactions of novel class of dimeric Ru(III) compounds Na2[trans-RuCl4(Me2SO)2(μ-L)] (L=ditopic, non chelating aromatic N-ligand). A preliminary investigation 156
Biological Properties of Irim, the iridium(III) analogue of (imidazolium(bisimidazole)tetrachlororuthenate) (ICR) 153
New anionic and neutral complexes of Ru(III) with nitrogen oxide 152
Synthesis, characterization and biological activity of copper complexes with pyridoxal thiosemicarbazone derivatives. X-ray crystal structure of three dimeric complexes. 151
Linking the future of anticancer metal complexes to the therapy of tumour metastases 151
In vitro cell cycle arrest,in vivo action on solid metastasizing tumors and host toxicity of the antimetastatic drug NAMI-A and cisplatin. 150
Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity 150
Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives. 150
Tumor cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells 149
Ruthenium-based compounds and tumour growth control (Review) 149
Hyperphosphorylation Maintenance Drives the Time-Course of G2-M Cell Cycle Arrest after Short Treatment with NAMI-A in KB Cells 149
Chitosan-coated alginate micro-particles delivery of active principles through conventional pelleted food - A study in Tilapia (Oreochromis niloticus) 149
PHARMACOLOGICAL APPROACHES TO SARS-CoV-2 INFECTION: FROM DRUG REPOSITIONING FOR COVID-19 TREATMENT TO DISEASE ARREST/PREVENTION WITH MoAbs AND NOVEL ANTIVIRALS 147
Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion. 147
Lysozyme stimulates lymphocyte response to ConA and IL-2 and potentiates 5-fluorouracil action on advanced carcinomas 141
CDK1 hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after shot treatment with NAMI-A in KB cells 140
Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A 139
Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenantrolines and acyclovir or penciclovir 137
Lysozyme-induced transcriptional regulation of tnf-α pathway genes in cells of the monocyte lineage 136
Treatment of residual metastases with Na[trans-RuCl4(DMSO)Im) and ruthenium uptake by tumour cells 135
Inhibition of endothelial cell functions and angiogenesis by the metastasis inhibitor NAMI-A 132
Modification of Lymphocytes of Peyer’s Patches-Mesentheric Lymphonodes Splean by Egg-White Lysozyme 132
Tumour cell uptake, G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells 128
Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin 127
The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy 121
Selection of Natural Compounds with HMGA-Interfering Activities and Cancer Cell Cytotoxicity 117
Totale 18.767
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.415
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.415
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.124 0 0 64 128 22 96 71 56 172 137 103 275
2022/20231.589 181 179 124 202 155 297 3 152 199 10 64 23
2023/2024938 84 55 33 52 95 57 114 305 9 15 48 71
2024/20252.674 18 150 483 187 204 286 160 149 299 256 197 285
2025/20265.937 434 404 529 573 499 539 893 206 626 790 238 206
2026/2027794 205 314 275 0 0 0 0 0 0 0 0 0
Totale 21.163